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Abstract:  Epstein-Barr  virus  (EBV)  is  classified  as  a  member  in  the  order  herpesvirales,  family  herpesviridae,
subfamily gammaherpesvirinae and the genus lymphocytovirus. The virus is an exclusively human pathogen and thus
also termed as human herpesvirus 4 (HHV4). It was the first oncogenic virus recognized and has been incriminated in
the causation of tumors of both lymphatic and epithelial nature. It was reported in some previous studies that 95% of the
population  worldwide  are  serologically  positive  to  the  virus.  Clinically,  EBV  primary  infection  is  almost  silent,
persisting as a life-long asymptomatic latent infection in B cells although it may be responsible for a transient clinical
syndrome called infectious mononucleosis. Following reactivation of the virus from latency due to immunocompromised
status, EBV was found to be associated with several tumors. EBV linked to oncogenesis as detected in lymphoid tumors
such as Burkitt's lymphoma (BL), Hodgkin's disease (HD), post-transplant lymphoproliferative disorders (PTLD) and T-
cell lymphomas (e.g. Peripheral T-cell lymphomas; PTCL and Anaplastic large cell lymphomas; ALCL). It is also linked
to epithelial tumors such as nasopharyngeal carcinoma (NPC), gastric carcinomas and oral hairy leukoplakia (OHL). In
vitro,  EBV many  studies  have  demonstrated  its  ability  to  transform  B  cells  into  lymphoblastoid  cell  lines  (LCLs).
Despite these malignancies showing different clinical and epidemiological patterns when studied, genetic studies have
suggested that these EBV- associated transformations were characterized generally by low level of virus gene expression
with only the latent virus proteins (LVPs) upregulated in both tumors and LCLs. In this review, we summarize some
clinical and epidemiological features of EBV- associated tumors. We also discuss how EBV latent genes may lead to
oncogenesis in the different clinical malignancies
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INTRODUCTION
Epstein-Barr virus (EBV) is classified as a γ-herpes
virus [1] and contains a linear DNA molecule about 172
kilo  bases  in  length.  It  affects  more  than 90% of  adult
population  worldwide  [2].  First  exposure  to  the  virus,
before  or  after  adolescence,  occurs  via  exchange  of
saliva  or  contact  with  the  airborne  virus  [3].  If  the
infection  does  not  become  clinically  silent,  infectious
mononucleosis is experienced by EBV-exposed persons.
This  infection  was  reported  worldwide  but
predominantly in the developing countries and by around
18 months of age, the majority of children in developing
countries are found exposed to the virus [4].
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Although EBV infection is lifelong, pathogenicity in the
host  is  limitted  unless  the  immune  sysytem  is
compromised.  Reactivation  of  latent  EBV  results  in
recurrent  infections  of  a  clinical  nature.  The  diseases
include those of a lymphocytic nature, namely infectious
mononucleosis,  Hodgkin’s  disease  (HD),  Burkitt’s
lymphoma  (BL),  post-transplant  lymphoproliferative
disorders (PTLD) and T-cell lymphomas and those of an
epithelial nature such as oral hairy leukoplakia (OHL),
nasopharyngeal  carcinoma  (NPC)  and  undifferentiated
gastric carcinoma [5]. The severity of EBV infection and
level of virus titer vary with the carcinoma type with the
highest titer for EBV being observed in undifferentiated
carcinomas  [6].  Infectious  mononucleosis  (synonyms
include  Pfeiffer's  disease,  Filatov's  disease,  kissing
disease,  glandular  fever  or  “mono”  in  North  America)
[7] is a primary self-limiting clinical syndrome that most
frequently  affects  young  adults,  although  other  age
groups  can  also  be  infected.  The  classic  clinical
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symptoms  of  this  condition  include  sore  throat,  fever,
fatigue,  malaise,  vomiting  and  loss  of  appetite  with
common  pathological  lesions  including  lympha-
denopathy, spleenomegaly, hepatomegaly and jaundice,
all of which may be detected in older adults [8]. Burkitt's
lymphoma  (or  Burkitt's  tumor)  is  a  tumor  of  the
lymphatic system (specially B lymphocytes). The name
was  coined  after  Denis  Parsons  Burkitt,  who  firstly
described  the  disease  in  1956  in  equatorial  Africa  [9].
Currently, BL is divided into three main clinical forms:
the  endemic,  the  sporadic  and  the  immunodeficiency-
associated BL and all forms related to EBV infectivity in
African and non-African countries [10, 11] (Fig. 1) will
be described in detail later. Hodgkin lymphoma (HL) is a
cancer  which  originates  from the  germinal  center  of  B
cells  with  a  unique  histological  picture  that  comprise
inflammatory fields with a minority of neoplastic cells. It
differs  from  the  other  B  cell  lymphomas  with  its
characteristic  clinical  and  pathological  manifestations
[12].  Post-transplant  lymphoproliferative  disorder
(PTLD)  is  also  a  kind  of  B-cell  immortalization
attributed  to  immunosuppressive  status  following
chemotherapy  for  organ  transplantation  surgery.  Such
patients  can  suffer  from  infectious  mononucleosis-like
lesions or may develop polymorphic B-cells proliferation
which  later  may  become  malignant  due  to  additional
mutational changes. This disease which is characterized
by  uncontrolled  proliferation  of  B  cells  was  known  to
have a strong association with EBV infectivity [13].
Although, EBV was originally isolated from Burkitt's
lymphoma biopsies, a major B cell lymphoma, it is now
considered  to  have  a  role  in  several  other  epithelioid
malignancies  [14].  Oral  hairy  leukoplakia  (OHL)  is  a
mucosal tumor firstly recognized and described in 1984.
It  is  a pathological lesion proved to be associated with
EBV  replication  and  mostly  occurring  in  people  with
HIV infection [15]. It was also reported in HIV negative
patients  when  firstly  observed  in  1996  in  a  patient
suffering  from  systemic  lupus  erythromatosis  [16].
Nasopharyngeal carcinoma (NPC) is the most common
malignant  tumor  of  the  nasopharynx,  worldwide,  also
known to be caused by EBV. This carcinoma varies from
the  others  of  the  head  and  neck  in  incidence,  causes,
clinical pictures and management. It is more common in
males than females and in the East Asians and Africans
than other  racial  groups of  people  [17].  EBV infection
was also known as the cause for a reasonable percentage
of  gastric  carcinomas  worldwide  [18,  19].  The  role  of
EBV in gastric carcinomas was confirmed by detection
of the viral  gene products like the EBV-encoded small
RNA  (EBER)  in  these  tumors,  in  addition  to  the
presence  of  clonal  EBV  [20,  21].
Additionally, an in vitro EBV infection of resting B
cells was known to lead to proliferation, immortalization
and  consequently  to  lymphoblastoid  cell  lines  (LCL).
These LCL were also shown to be latently infected with
EBV, and hence provided a suitable laboratory model for
investigation  of  EBV  latency  and  virus-driven  B  cells
carcinogenesis  [22].  LCL  have  also  served  as  EBV
antigen presenting cells in several immunologic methods
and tests [23, 24] including the development of human
monoclonal antibodies [25, 26]. The efficiency of EBV-
mediated  CTL  proliferation  increased  with  the  use  of
mitogens  like  phytohemagglutinin  and  lipopoly-
saccharide  [27],  pokeweed  mitogen  [28]  and  some
immunosuppressive drugs like the cyclosporine A which
prevents  the  T  cell-mediated  cytotoxicity  of  EBV-
infected  B  cells  [29  -  31].
In a variety of studies, EBV was proved to perform
its  oncogenic  capacity  by  an  expression  of  what  is
known  as  latent  genes,  namely  the  latent  membrane
proteins  (LMP1,  LMP2A,  and  LMP2B)  and  the  EBV-
determined  nuclear  antigens  (EBNA1  and  EBNA2).
LMP1  was  reported  as  the  major  oncogenic  factor  of
NPC  development  and  were  detected  in  80%-  90%  of
NPC  tumors  [32].  In  addition  to  its  direct  oncogenic
potential,  LMP1  was  also  known  to  play  a  role  as  an
immunosuppressive  agent  against  NPC,  which  allows
NPC  to  develop  quietly  [33,  34].  The  importance  of
LMP1 as an oncogenic factor was confirmed in several
studies by demonstrating that tumor cells are much more
sensitive  to  chemotherapeutic  agents  when  LMP1
expression  was  inhibited  [35].  Previously,  the  exact
contribution  of  LMP2  and  EBNA  to  cellular
tumorgenesis  was  uncertain  but  later,  due  to  more
advanced research approaches, the role of these factors
in  the  EBV-induced  tumorgenesis  is  well-  studied  and
recognized.  Early  data  suggested  that  LMP2  was
required for tumor cell survival but the more recent data
showed  that  LMP2  plays  more  diverse  and  critical
functions  in  the  process  [36].  LMP2A  was  proved  to
downregulate  the expression of  the transcription factor
of NF-κB- resulting in a decrease of  LMP1 expression
[37].  In  addition,  LMP2A  is  responsible  for  NPC
becoming more migratory and invasive [38]. EBNA1 is
the  factor  reported  to  bind  the  viral  genome  to  the
cellular  genome,  and  in  so  doing,  linking  viral  DNA
replication  with  the  cells  division  [39].  EBNA2  was
known to serve as a powerful LMP1 transactivator [40].
Many  previous  studies  have  led  to  the  well-
established fact that EBV is responsible for tumorgenesis
in lymphoid and epithelial cells both during the natural
course  of  infections  as  well  as  in  the  induced
lymphoblastoid  cell  lines  (LCL).  In  this  review,  we
attempt  to  summarize  the  clinical  outcomes  and  some
epidemiological  features  associated  with  the  different
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tumors  induced  by  EBV  in  both  lymphoid  and
epithelioid cells. We also demonstrate the exact genetic
elements involved and the roles played by each separate
genetic entity during the transformation process.
HISTORICAL BACKGROUND
The  history  of  EBV  infection  goes  back  to  1958
when  the  English  surgeon,  Denis  Burkitt,  who  was
working in Uganda, observed and reported a frequently
occurring cancer affecting the children in his work area
and  equatorial  Africa  in  general  [9].  This  cancer  was
later  officially  named  Burkitt's  lymphoma  (BL)  or
Burkitt's disease (BD) after the infection was recognized
and scientifically well-established. A strong correlation
between  the  distribution  of  BL  and  the  climatic  and
geographical  conditions  in  the  infection  areas  was
documented;  consequently  an  idea  of  a  vector  borne
virus responsible for the condition was suggested [41].
Afterwards, using an electron microscopic examination
of a biopsy from BL, Epstein, Achong and Barr isolated
and identified herpes virus-like particles and hence the
virus  name  in  1964  [42].  As  confirmatory  evidence,  it
was  shown  by  serology,  in  the  late  1960s,  that  BL
patients had high antibody titers to the antigens of EBV
[43].  Using  serological  assays,  EBV  was  then  also
confirmed  as  the  causative  virus  for  infectious
mononucleosis  and  it  was  also  demonstrated  as  a
common  etiological  agent  for  undifferentiated  NPC
development  and  many  other  cancers  [44,  45].  The
transformation capability  of  EBV was later  recognized
and documented when the virus was shown to transform
resting B cells efficiently in vitro and also cause tumors
in other primates [46 - 48]. Subsequently, many research
outputs  have  indicated  that  EBV  is  responsible  for
different  human  tumors  of  B  cells  origin  such  as
Hodgkin's  disease  (HD)  and  the  lymphoproliferative
disorders  observed  in  immunosuppressed  individuals.
Some  T-cell  lymphomas  and  epithelial  malignancies
were  also  linked  to  EBV  as  will  be  discussed  later.
Multiple  copies  of  the  circular  EBV  genome  were
detected in the tumor cells of all these malignancies and
EBV-latent  gene  expression  was  confirmed as  a  major
marker in the development of these malignant conditions
[49]. In conclusion, to confirm the role of the EBV in the
neoplastic  transformation  of  mammalian  cells,  many
research studies pertaining to virology, clinical and the
genetics  of  the  virus  were  intensively  carried  out  by
researchers  in  many  parts  of  the  world.  They  are
complied and summarized here for the purposes of this
review.
GENETICS OF EBV
In total, herpes viruses have been studied intensively
at the genetic levels at various points in time [50 - 52].
EBV,  in  particular,  received  a  special  attention  for
genetic  studies  and  analysis  when  recombination
techniques became available for the virus in mammalian
cells [53 - 55]. The different genetic components of the
EBV  genome,  and  their  functions  were  identified
following  generation  of  mutants  through  cloning
techniques.  When characterized some of  these mutants
were  also  found  to  have  potentially  useful  medical
properties such as those suggested as vaccine candidates
[56]. The link between the various genes and biological
behaviours such as the transforming property of the EBV
was documented in many studies [57 - 59].
The EBV genome consists of double-stranded, linear
DNA  molecule  coated  by  the  capsid  protein  and
surrounded by the  tegument  layer  which is  surrounded
by an envelope composed of bilayer proteins sandwiched
by lipids [60]. The size of the genome varies; it was first
reported that EBV genome is about 172 kilo base pairs
(Kbp) in length [61] but later it was shown to be about
192 kilo base pairs and to encode about 85 genes [62].
Among all herpes viruses, the EBV genome was the first
to be sequenced completely for many strains of the virus
[61,  63  -  65]  and  recently  mapped  [66].  A  series  of
repeated DNA sequence accounts for 0.5 kb as terminal
repeats at the end of the linear genome observed in the
nucleus  of  cells  during  latency of  the  virus  in  infected
cells. They are about 10-20 copies for each infected cell
[67].  Long  and  short  sequence  domains  in  the  EBV
genome were also reported as divided by internal repeat
sequences (IRs)  and strain variation in the repeat  copy
numbers was also noted [68].
Based on the sequence organization of the EBNA 2,
3A, 3B, and 3C genes of EBV, two subtypes of the virus
have been recognized [69]. The prototype strain of EBV,
named  as  B95-8,  was  sequenced  and  the  open  reading
frames  (ORFs)  and  the  sites  for  the  transcription
processes  are  readily  recognized  and  the  virus  has
proved  to  have  a  coding  potential  of  around  80
characterized and non-characterized proteins [61]. After
analysis  of  the  sequences  of  other  EBV  strains,  more
four  open  reading  frames  (BVLF1,  BDLF3.5,  BFR1A
and  BGLF3.5)  have  been  identified.  The  function  of
BVLF1 and BDLF3.5 are unknown so far  and BFR1A
was  suggested  to  play  a  role  in  the  DNA  packaging
whereas BGLF3.5 was recognized as a tegument protein
[70].  Generally,  various  aspects  of  the  EBV  genome
have  been  intensively  studied  to  correlate  the  basic
genetic  components  and  their  expression  with  the
biological  behaviour  of  the  virus,  which  include
infectivity and pathogenesis, immune responses, latency
and  reactivation  and  the  virus  transformation  potentia.
These studies were especially possible after the advent of
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molecular approaches in virology.
EBV REPLICATION CYCLE
In order to replicate, EBV requires sequential steps
of  viral  protein  synthesis.  The  first  expressed  proteins
are  the  immediate  early  proteins  which  serve  as
transactivators  that  enhance  the  synthesis  of  the  early
and  late  proteins  required  for  DNA  replication  and
production  of  the  progeny  infectious  virus.  The  two
major immediate early protein transactivators are named
Zta and Rta and they function in the initiation of the lytic
EBV replicative cycle [36, 71]. The significance of these
two  transctivators  for  EBV  replication  has  been  well
documented  through  mutants  deficient  in  either  Zta  or
Rta  which  showed  only  poor  replication  levels  [72].
Both  lymphoid  and  epithelial  cells  can  be  infected  by
EBV  through  different  attachment  and  entry
mechanisms. To enter B lymphocytes, viral attachment
protein  (VAP),  also  called  gp350,  binds  to  the  CD21
receptor  on  the  cell  membrane;  additionally,  the  viral
gp42 also attaches to the MHC class II molecules at the
cell  surface.  Both  of  these  interactions  allow  the  viral
envelope to fuse to the cell membrane and consequently
the virus gains access to B cells [73, 74]. For EBV entry
into epithelial cells, viral protein BMRF-2 interacts with
the β1 integrins in the cell membrane, and viral proteins
gH and gL interact with the cellular αvβ6/8 integrins and
these  two  processes  enhance  the  fusion  between  the
epithelial  cell  membrane  and  the  viral  envelope  and
ultimately  result  in  the  virus  entering  the  cell  [75].
Following  entry  of  EBV  into  the  cell,  an  uncoating
process takes place in the cytoplasm in which the virus
sheds  the  protein  coat  and  the  viral  DNA  will  be
transported  to  the  cell  nucleus.  In  both  types  of  cells,
EBV can undergo lytic replication cycle resulting in the
production of infectious virions. The lytic replication of
EBV in  B cells  is  usually  observed to  occur  following
reactivation of latent virus whereas in epithelial cells it
has  been  observed  to  happen  directly  in  primary
infection  after  viral  entry  to  the  cell  [60].  The  EBV
circular  latent  genome  turn  to  a  linear  form  after
reactivation  to  adopt  the  lytic  replication  cycle.  Three
consecutive stages are required during EBV replication
with  three  types  of  genes  expressed;  immediate-  early
(transactivators),  early  gene  products  include  BNLF2
serving  in  replication,  metabolism  and  blockade  of
antigen  processing  and  the  late  gene  products  which
express the structural viral  proteins like the capsid and
the BCRF1 protein, which helps the virus to escape the
host immune response. Generally, EBV lytic replicative
cycle does not necessarily result into lysis of the cell as
the  virus  is  released  from the  infected  cell  by  budding
[60,  76].  Thus  while  the  EBV  replicative  cycle  shows
different  features  at  the  early  phase  of  replication  and
entry processes, it adopts similar pathways to complete
the cycle in either the lymphatic or epithelial cells.
EBV INFECTION LIFE CYCLE
EBV is more likely transmitted from infected host to
the  susceptible  host  via  saliva.  Following  the  primary
infection,  EBV  can  replicate  extensively  in  epithelial
cells  of  the  nasopharynx  and  consequently  cell  lysis
releases  the  virion,  and  the  virus  spreads  to  salivary
glands  and  oropharyngeal  lymphoid  and  epithelial
tissues. B lymphocytes are then infected as they circulate
in close to oropharyngeal epithelial cells. The virus then
circulates  throughout  the  body  through  the  infected  B
cells. Within the B cells, EBV may either lead to a series
of  lytic  replication  cycles  or  it  may  show  differential
expression of the latent genes which will allow the virus
to become latent in the cells [77, 78]. As a result of this
continuous  replication  of  the  virus,  viremia  will  occur
and  consequently  the  lymphatic  system  such  as  the
peripheral B lymphocytes, spleen, liver and lymph nodes
will be infected so that EBV can remain latent in these
sites  as  well  [49].  When  EBV  establishes  itself  as  a
latent virus it does so as an episomal virus in which the
viral  genome  is  found  as  a  self  replicating  extra
chromosomal DNA and is thus known as an episome and
latency recognized as episomal latency [79]. Depending
on  the  differential  expression  of  EBV-specific  genes,
three  different  types  of  latencies  were  recognized,
latency I, II and III [49]. For several reasons relating to
immunosuppression, EBV sporadically reactivates from
latency [77, 78]. Following reactivation, EBV shedding
from saliva of infected host will occur intermittently and
hence  saliva  constitutes  the  major  source  for
transmission  from  infected  to  healthy  individuals;
however, transmission of the virus via blood transfusion,
sexual contacts and tissue transplantation have been also
reported [80, 81]. Both in vivo and in vitro infection of
EBV leads  to  transformation and immortalization of  B
cells [49]. The in vitro transformation of B cells can be
diagnostically  confirmed  through  the  EBV-specific
immunofluorescence  assay  [43]  while  the  in  vivo
transformation resulting in several kinds of malignancies
detailed below. Subsequent to B cell immortalization by
EBV  infection,  T  suppressor  lymphocytes  were  also
observed  to  play  a  cytotoxic  role  and  hence  the  viral
counts  are  reduced  with  a  dramatic  reduction  in  the
circulating  B  cells.
EBV LATENCY AND REACTIVATION
As  a  herpes  virus,  EBV  was  known  to  establish
latency  after  the  primary  infection  in  both  B  cells  and
epithelial  cells  where  it  persists  as  an  episome  in  the
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nucleus without productions of virions. The linear DNA
molecule  of  the  virus  circularizes  and only  some EBV
genes are expressed during latency stage. As mentioned
earlier  three  different  latency  programs  (I,  II  and  III)
were reported for  EBV; during each program the virus
expresses a set of a latency associated genes. The latency
programs  adopted  by  the  virus  in  B  cells  are  different
from  those  in  epithelial  cells  and  for  each  type  of
latency, a distinct set of viral proteins and transcripts will
be  produced  [82,  83].  Within  B cells,  all  three  latency
programs  can  take  place,  starting  from  Latency  III  to
Latency  II  to  Latency  I,  whereas  upon  epithelial  cells
infection  only  the  latency  II  program  is  found.  When
EBV infects the a B cell, the latency III program starts
first with a considerable number of proteins expressed to
cause cell transformation. Less gene expression occurs in
the move towards latency II to differentiate the B cells
into memory cells and finally lesser genes expressed to
enter the stage of latency I [84]. The EBNA-1 protein is
expressed by the EBV during latency to allow the EBV
genome to replicate during memory B cell division. The
latency associated with EBV infection of B-lymphocytes
is  an  essential  mechanism  for  virus  persistence.  The
replication of EBV in epithelial cells is necessary for the
release  of  infectious  virus  into  saliva.  It  was  well-
established that the EBV Latency III and II infections is
a characteristic features of B-cells whereas Latency II is
that of the oral epithelial cells and NK- or T-cells all of
which can result in different kinds of malignancies [85].
The  ultimate  and  exact  requirement  of  EBNA2  and
LMP1 in transformation of B cells in vitro  studies was
confirmed by using of an EBV recombinant deficient in
some  latent  genes.  A  substantial  role  for  EBNA-LP,
EBNA3A  and  EBNA3C  in  latency  process  was  also
suggested when these recombinants were used [86]. The
expression of EBV- latency associated genes during the
latency programs is summarized in Table 1.
Table 1. Expression of EBV-latency associated genes during latency programs [87].
Latency program
EBV gene expressed
  occurrenceEBERs EBNA1 LMP1 LMP2A EBNA2 EBNA3
0 + ND - + - -
Memory B cells in
peripheral blood
I + + - - - - BL, PEL
II + + + + - - HD
III + + + + + + PTLD
IV ND ND - ND + ND
Infectious mononucleosis,
PTLD
BL, Burkitt lymphoma; HD, Hodgkin lymphoma; ND, Not determined; PEL, primary effusion lymphoma; PTLD, post-
transplant lymphoproliferative disease; +, expressed; -, not expressed.
EBV latent infection in B cells can reactivate due to
immunosuppression  of  the  infected  individual;  it  can
also reactivate in vitro to switch to lytic viral replication
and this has been accomplished by stimulating the B cell
receptor  through  several  mechanisms.  It  had  been
observed that patients with polymyositis or rheumatoid
arthritis  undergo  EBV-associated  lymphomas  more
frequently when treated with methotrexate (MTX) than
when  treated  with  other  immunosuppressive  agents.
Consequently, MTX was used for an in vitro reactivation
and release of infectious EBV from latently infected B or
epithelial  cells  [88].  In  another  study,  the  potential  of
monochloramine  (NH2Cl),  produced  during  H.  pylori
infection to the gastric epithelia, to reactivate virus was
also  examined  and  the  results  suggested  that  NH2Cl
induces  EBV  lytic  replication  in  gastric  epithelium  if
latently infected with EBV [89]. Several in vitro studies
for EBV reactivation were done with cell lines derived
from Burkitt lymphoma as they are very permissive for
the  lytic  cycle  of  the  virus  when  treated  with  various
immunosuppressive  agents  as  compared to  LCLs [90 -
92].
The issue of understanding EBV latency in infected
cells  and  reactivation  from  latency  as  well  as  the
mechanisms  adopted  for  transformation  of  normal
human B or epithelial cells into tumor cells are important
for developing and establishing methods to prevent and
pave the way for improved clinical management of these
EBV-associated neoplasms.
FACTORS  REGULATING  EBV-ASSOCIATED
ONCOHENESIS
The  various  factors  controlling  EBV-associated
oncogenesis can be categorized and summarized in the
following:
Genetic:  The  oncogenic  capacity  and  properties  of
EBV  are  recognized  through  its  in  vitro  transforming
effects. Following infection of primary human B cells in
vitro,  EBV  induces  proliferation  resulting  into  the
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development  of  lymphoblastoid  cell  lines  (LCLs).  The
genes  of  six  EBV  nuclear  antigens  namely  EBNA1,  2
3A,  3B,  3C  and  EBNA-LP  as  well  as  three  latent
membrane  proteins  namely  LMP1,  2A  and  2B  are
expressed  in  these  induced  latently  infected  cells.
Likewise,  these  proteins  are  expressed  at  the  early
phases of natural infection [93, 94]. EBNA2 is reported
as  the  central  transcription  factor  for  both  viral  and
cellular  genes  expression  and  is  responsible  for  B  cell
proliferation  and  is  expressed  in  LCLs  [95].  LMP1
expression, in turn, is regulated by EBNA2 and serves as
an active receptor for tumor necrosis factor, an essential
apoptotic element [96]. LMP1was also reported to signal
in the B cell similar to CD40- CD40 ligand interaction
showing  similar  functional  properties  with  activated
CD40  [97].  However,  in  the  lack  of  EBNA2  in  EBV-
proliferating B lymphocytes exists, CD40 activation and
LMP1  expression  leads  to  similar  phenotypic
characteristics, the continuous survival of the cell [98].
On the other hand, interestingly both the activated CD40
and LMP1 expression also prevented B cells  apoptosis
[99,  100].  Additionally,  experimentation  with  a
transgenic  mice  revealed  that  LMP1  mimics  CD40
signaling  of  B  cells  differentiation  during  natural
infection  [101].  Generally,  the  role  of  different  EBV-
encoded  latent  genes  in  tumor  formation  is  recently
complied  [102]  and  summarized  in  Table  2.
Table 2. The role of different EBV-encoded latent genes during latency and tumorigenesis [102].
Latent genes Role of genes
EBNA-1 Transactivator of viral latent genes and host genes; responsible for episome replication, segregation and persistence of viral
genome; involved in p53 degradation and oncogenesis.
EBNA-LP Transcriptional co-activator of EBNA-2-dependent viral and cellular gene transcription; It is essential for EBV-mediated B-cell
transformation.
EBNA-2 Activates viral and cellular gene transcription for transformation.  It  is critical for EBV-mediated B-cell transformation.
EBNA-3A A co-activator of EBNA-2, downregulate cMyc transcription and block EBNA-2 activation effects; and induce CDKN2 and
chemokines. It is essential for EBV-mediated B-cell transformation.
EBNA-3B A co-activator of EBNA-2; dispensable for B-cell transformation; viral tumor suppressor; and up regulates CXCL10. EBNA-3B-
knockout induces DLBCL-like tumors.
EBNA-3C ates with EBNA-2 host CXCR4 and CXCL12 genes; overcomes EBV-infection-mediated DNA damage response; promotes cell
proliferation; induces G1 arrests; It is essential for EBV-mediated B-cell transformation.
LMP-1 Mimics the constitutively active form of CD40, activates NF-κB, JNK and p38 pathways; is critical for EBV-mediated B-cell
transformation.
LMP-2A Responsible for  constitutive activation of the ERK/MAPK pathway224; blocks antigen-dependent BCR signaling; induces B-
cell lymphoma in transgenic condition. It is important but not essential for in vitro primary B-lymphocyte growth transformation.
EBER Augments colony formation and induces growth; confers cells resistance to PKR-dependent apoptosis; induces cytokines and
modulates innate immune response; contributes to EBV oncogenesis.
miRNAs Has a role in sustaining latently infected cells. BHRF1 miRNA and BART miRNAs interfere with apoptosis.
BART,  BamHI-A region  rightward  transcript;  BHRF1,  BamHI fragment  H rightward  open  reading  frame 1;  EBV,
Epstein-Barr  virus;  EBER,  EBV-encoded  nuclear  antigen;  EBNA,  EBV  nuclear  antigen;  LMP,  Latent  membrane
protein, BHRF1, BamHI fragment H rightward open reading frame 1; MAPK, mitogen-activated protein kinase; NF-
κB, nuclear factor-κB; BCR, B cell receptor; PKR, RNA-dependent protein kinase; JNK, c-Jun N-terminal kinase.
Viral: Strain variation was suggested to be the main
factor  for  the  increased  incidence  of  EBV-associated
malignancies in specific populations. Some EBV strains
indeed  possess  more  distinct  biological  properties  as
compared to others. The difference between EBV types
1  and  2  is  clearly  observed  in  sequence  variation  and
other EBV variants have been shown based on the viral
genome sequence polymorphism of EBNA 2 and 3[103,
104]. Changes among different EBV strains also reside
in sequence changes of EBNA1, BZLF1 and LMP1 [105
-  107].  Investigations  into  EBV  strain  variation  using
restriction  fragment  length  polymorphisms  (RFLP)
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compared  EBV  strains  predominately  responsible  for
NPC  in  Southern  parts  of  China  [108].  Similar  EBV
genetic  polymorphism  was  also  reported  when  NPC
samples  from  Alaska  and  Caucasian  America  were
investigated;  but  no  such  polymorphism  was  observed
for  NPC  samples  from  the  Mediterranean  and  Africa
[103]. Genetic analysis for EBV-associated malignancies
indicated that the HIV co-infection is another potential
factor regulating the incidence of the lymphomas as HIV
infection  is  associated,  in  most  cases,  with  multiple
strains  of  EBV  [109].
Environmental: The endemic patterns of many EBV-
associated  tumors  were  initially  apparent  as  EBV  was
originally  isolated  from  samples  of  African  Burkitt’s
Lymphoma (BL) [42] and this tumor was observed with
high  incidence  in  subequatorial  Africa  [41].  Endemic
cases  were  also  found  associated  with  chronic  malaria
and  EBV  infectivity,  whereas  sporadic  cases  mostly
occurs  outside  of  Africa  and  were  associated  with  the
ileocaecal region, with the jaw less often affected as in
the endemic type. Arboviral infection and plant extracted
herbs used as therapeutic agents for some diseases have
also been suggested as potent tumor-promoting cofactors
for EBV induced oncogenesis [110]. The parotid gland
tumors  and  the  T-cell  lymphomas,  due  to  EBV  have
been found to develop with increased frequency among
Greenland  Eskimos  and  Taiwanese  and  Japanese
respectively  [111,  112].  As  per  the  age  and  gender  as
factors,  patients  with  T-cell  lymphomas  were  found
either middle-aged or elderly, and no gender preference
for  this  disease  has  been  observed  [113].  Study  of  the
epidemiology  of  EBV-associated  nasopharyngeal
carcinoma (NPC) indicated high incidence occurrence in
the southern Chinese and an elevated incidence in Inuit
populations  and  in  Mediterranean  Africa  [114].  The
prevalence  rates  of  NPC  were  particularly  elevated  in
populations of Southeast Asia natives, the Arctic region,
North African Arabs and some parts of the Middle East.
This  was  suggested  to  result  from  the  consumption  of
preserved  food  during  early  ages  of  life  which  could
predispose to a high risk of NPC development in these
populations.  Risk  factors  for  NPC  development  like
cigarette smoking, exposure to formaldehyde and wood
dust have been also recorded [114]. The co-factors that
contribute to the development of Hodgkin’s lymphoma
(HL) and gastric carcinomas are currently unknown but
environmental and immune components due to immune
impairment  are  likely  factors.  It  is  likely  that
environmental  or  genetic  factors  increased infection of
distinct susceptible cell populations and activate cellular
pathways  that  are  highly  synergistic  with  EBV  genes
expression which affect cell growth [115].
EBV- ASSOCIATED LYMPHOID TUMORS
B-cells Lymphomas
It  has  been  documented  in  several  reports  in  the
medical  literature  that  EBV  is  frequently  linked  with
many  B  cells  lymphomas,  mostly  observed  in
immunosuppressed  individuals.  Although  they  look
similar  on  pathological  grounds,  these  EBV-linked  B-
cells  lymphomas  were  shown  to  heterogeneous  on  the
molecular  and  clinical  levels,  as  discussed  in  the
following  sections:
Burkitt's  lymphoma:  This  lymphoma  was  the  first
malignancy known to be attributed to EBV. It was firstly
observed in central Africa and due to its strict correlation
with  malaria  endemicity,  it  was  suggested  that  an
infectious organism might be involved. Eventually and
following EBV recognition, it was confirmed that EBV
is  the  major  cause  of  BL.  The  natural  history  of  this
association was recently reviewed by Moormann et  al.
2011  [116].  The  precise  contribution  of  EBV  in  the
pathogenesis  of  this  lymphoma  has  been  extensively
documented.  Despite the fact  the EBV was detected in
biopsies of some BL, some other studies suggested that
EBV  infectivity  occurs  before  B  cells  proliferation  to
induce  malignant  conversion  [117].  EBV  is  also
suggested to have a powerful role in the sporadic form of
BL as the episomal defective genome of the virus have
been isolated from some sporadic cases of BL tumors in
USA [54].
BL has been reported to occur with an incidence rate
of  about  5-  10  cases  per  100,000  children  annually  in
equatorial and central Africa where it  became endemic
[110].  Higher  incidences  of  this  endemic  form  of  BL
were  also  for  North  Africa,  South  America  and  the
Middle East regions [118]. Less endemic situations were
observed  in  African  countries  like  Egypt  [119]  and
Algeria [120] where the incidence of malaria is also at a
low level.  Generally,  sporadic  BL occurred  worldwide
but  at  a  lower  frequency  as  compared  to  the  endemic
form  [110].  Although  it  can  affects  adults,  BL  most
commonly  affects  children  where  it  constitute  the
majority of B cell lymphomas during childhood, whereas
in adults it accounts for less than 10% of all lymphomas
[121].  The incidence is  reported to  peak at  the ages of
about 5-8 years old and is more commonly observed in
males as compared to females [122, 123].
At  the  cellular  level,  chromosomal  translocations
within B cells are the consistent genetic feature of all BL
tumors. These translocations occur in the region of the c-
myc oncogene (mainly involves the 8q24 of the long arm
in the chromosome number 8), and in the region of the
immunoglobulin heavy chain gene (in the chromosome
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14) or in the region of the immunoglobulin light chain
genes  (in  chromosome  2  or  22).  The  activity  of
immunoglobulin genes together with the germinal centre
of B cell proliferation stimulated through EBV infection
were  all  suggested  to  be  major  attributing  factors  for
selection, generation and proliferation of B cells which
basically harbor a c-myc translocation [110]. At the virus
level,  the  only  protein  factor  being  consistently
expressed  and  detected  during  BL  formation  is  the
EBNA1  protein  [35,  124].  In  another  study,  LMP1
together with the EBNA2 were reported expressed in a
small  numbers  of  cells  in  some  cases  of  the  endemic
form of BL [125]. In an in vitro  culture of some EBV-
positive  BL  tumors,  other  EBNAs  were  also  seen
expressed  beside  the  LMPs  [35].
Clinical presentation of endemic BL mostly includes
obvious  tumors  in  the  mandible  and  maxilla  with  the
abdominal  organs  being  involved  less  frequently.
Patients commonly showing swelling of the affected jaw
bones  and  the  lymph  nodes  in  the  neck,  and  jaws  are
rapidly  enlarged  without  tenderness  [126].  In  the
sporadic cases of this lymphoma, abdominal and pelvic
organs (namely ileum, caecum and mesentry) are usually
involved with the other abdominal and glandular tissues
(e.g. tonsils and thyroid) seen affected in some cases but
to  a  lesser  extent  [127].  Patients  of  BL  are  commonly
presented to the Gastroenterology clinics with abdominal
pain, ascites, abdominal distension and signs of intestinal
obstruction.  BL  has  also  been  observed  to  occur  as  a
consequence  of  immunodeficiency,  mostly  in  people
with HIV/AIDS infections where it accounts for 30% to
40% of non-Hodgkin lymphoma [128], so much so that
it  used  to  be  a  clinical  marker  for  AIDS.  BL was  also
detected  with  conditions  of  congenital  immuno-
deficiences  and  organ  transplants  patients  who  take
immunosuppressive  drugs  [129].
Fig. (1). Pathogenesis of Burkitt's lymphoma: This figure indicates the role of some cofactors and EBV genetic entities involved in
the development of BL in African population as illustrated by Brady et al. (2007) [11].
For accurate diagnosis of BL, lesion biopsy is always
performed  and  CSF  and  bone  marrow  are  usually
examined.  Cytology  of  pleural  fluid  and  ascitis  was
routinely  employed  to  arrive  to  a  definitive  diagnosis.
Radiographic  applications  such  as  the  magnetic
resonance imaging (MRI) and CT scanning are applied
at  diagnosis  and  then  throughout  the  infection  course.
Molecular biological techniques were mostly employed
to  distinguish  between  BL  and  the  other  large  B  cells
lymphomas [130]. Although endemic BL was known to
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be  highly  sensitive  to  chemotherapy,  sporadic  and
immunodeficiency-associated  BL  are  less  sensitive
[122].  Different  regimens  of  chemotherapy  have  been
tried with different success rates as described by Okebe
et al. in 2006 [131]. Intensive chemotherapy resulted in a
very successful treatment for children with BL. In adults,
good  results  were  obtained  when  chemotherapeutic
regimens  were  used  in  combination  with  rituximab
(monoclonal  antibody)  [132].  Non-intensive  chemo-
therapy  with  immunosuppressive  agents  such  as
cyclophosphamide and methotrexate was proved useful
to  manage  the  endemic  form  of  BL  in  developing
countries in Africa as reported by Beogo et al. in 2011
[133]. In sporadic or immunodeficiency-related BL, low-
intensity  infused  doxorubicin,  cyclophosphamide  with
vincristine, prednisone and rituximab treatment was seen
highly  effective,  particularly  in  adults  [134].  Bone
marrow or stem cell transplants are proposed in recurrent
cases  of  BL  and  surgery  had  also  been  proposed  and
used  if  intestinal  obstruction  is  evident  and  if  the
abdominal  tumors  are  small  and  absolutely  resectable.
The mainstay action for prevention of BL is the vaccine
development  for  EBV  and  malaria,  particularly  where
malaria is endemic [126].
Hodgkin's  disease  (HD):  The  first  report  that
suggested HD (also known as Hodgkin's lymphoma, HL)
is attributable to an infectious microorganism is made by
MacMahon in 1966 [135]. Later, and due to detection of
high levels of antibody specific to EBV antigens in the
sera of patients with this lymphoma, the infectious agent
incriminated as the cause of HD was claimed to be EBV
[136].  Furthermore,  it  was  shown  that  high  levels  of
antibodies to EBV antigens were detected several years
before  HD  development  [12].  As  a  matter  of
confirmation, several other investigations to confirm the
association  between  HD  development  and  EBV  via  in
situ  hybridization  techniques  were  carried  out  and
reported [57, 137, 138]. Despite the fact that EBV was
detected over the course of HD, cases of EBV-negative
HD  as  a  relapse  of  the  previously  EBV-positive  HD
lymphoma  have  been  observed  and  reported  [139].
Explicit  epidemiological  and  clinical  differences
between the EBV-associated and EBV-negative forms of
HD  tumors  has  been  demonstrated  and  it  has  been
claimed  that  HD  due  to  EBV  is  characterized  with
multicellularity and commonly observed more in males
than females [140]. Another interesting epidemiological
feature  of  HD  is  that,  in  USA,  EBV-related  HD  was
more commonly observed among Hispanics and Asians
than  Whites  or  African  Americans  populations  [33].
Similar  findings  were  observed  in  studies  in  the  UK
where an intimate association between EBV-positive HD
and  South  Asian  racial  groups  of  people  was  noted
especially in children [141]. As for age susceptibility, it
was observed that EBV-positives cases of HD were more
commonly  seen  in  older  patients  (above  55  years)  and
younger  children  (below  10  years)  whereas  in  young
adults it is mostly EBV-negative [142]. This fact has led
scientists  to  categorize  HD  into  three  disease  forms
based on the age group of patients: Childhood HD which
is EBV+ve (known as MC type), young adults HD which
is  EBV-ve  (known  as  NS  type)  and  older  adults  HD
which is also EBV+ve (also known as MC type) [142].
The development of HD also correlated with acquired or
congenital  immunosupprression  [39]  and  the  overall
incidence of HD was reported to be higher in HIV and/or
AIDS patients with most of these lymphomas recognized
as EBV-positive [143].
As for the genetic basis of this tumor, LMP1 proved
to have an essential tumorgenesis of B cells and its high
levels  of  expression  was  used  to  explain  the  obvious
clinical  and  morphological  variations  between  EBV-
positive  and  EBV-negative  forms  of  HD  [140].  Some
observations  had  also  showed  an  association  between
LMP1 and other genes expression suggesting that LMP1
upregulated these genes in an in vitro primary HRS cell
cultures (e.g. IL-10 and TRAF1). Therefore, in contrast
to EBV-negative HD forms, these genes are more likely
to  be  expressed  in  EBV-  positive  HD  [144  -  146].
Immunohistochemical  assays and genetic studies using
biopsies of HD also revealed that cultures of HRS cells
of EBV-positive HD cases express LMP1 to high levels
but not EBNA2 [147 - 149].
The  most  salient  symptomatology  of  HD  is  the
painless swelling in one or more lymph nodes especially
those of the neck, underarm and the groin. Some other
patients have symptoms like fever, night sweats, fatigue,
total body itching, weight loss, bone pain and increased
susceptibility  to  infections  as  recently  reviewed  by
Movva  [150].
Detection  of  abnormal  cells,  referred  to  as  Reed-
Sternberg cells,  by the pathologist  following biopsy of
an enlarged lymph node is the first line of HD diagnosis.
Radiographic  imaging  such  as  CT  scanning,  MRI,  or
PET  scanning  may  also  be  employed  to  determine  the
stage of HD. Immunohistochemistry was also employed
as  the  constitutively  nuclear  encoded  NF-κB  from  the
HRS  cells  can  be  detected  [151].  The  treatment  of
Hodgkin lymphoma (HL) depends on the direct medical
intervention using chemotherapy and radiotherapy; stem
cells  transplantations  were  also  recommended  in
relapsed cases, although about 20% of patients were seen
not  responsive  to  that  treatment  [152].  Brentuximab
vedotin, which was approved in 2011, made great shifts
in the treatment of HL and other novel therapeutics are
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expected  to  pave  the  way  for  future  improved  HD
treatment [153]. A combination of Brentuximab vedotin
and  Rituximab  was  also  implemented  to  help  the
immune  system  kill  lymphoma  cells  with  some  side
effects  encountered  [154].  Radiation  therapy  to  kill
lymphoma cells had also been tried to shrink tumors and
help  control  pain  with  better  results  obtained  when
combined  with  chemotherapy  [155].
Post-transplant  lymphoproliferative  disorders
(PTLDs):  They are defined on pathological  grounds as
combinations  of  lesions  progressing  from  atypical
polyclonal  B  cells  proliferation  in  immunodeficient
individuals  to  more  aggressive  monomorphic
lymphomas  which  continue  as  malignancy  even  after
immunity reconstitution [156]. On clinical grounds, they
are defined as lymphoproliferative disorders observed in
the tissue transplanted patients as they are usually under
immunosuppressive  therapy  and  also  in  those  who  are
congenitally immunodeficeint individuals such as those
suffering from Wiscott-Aldrich syndrome and X-linked
lymphoproliferative syndrome. They are also frequently
observed  in  AIDS  patients  who  may  also  experience
similar tumors of B-cell origin [157]. Although many of
these  B  cell  proliferation  conditions  derived  from  the
patient himself, in some cases these proliferated B cells
were  reported  originated  from  the  donor  [158].  The
overwhelming majority of these PTLDs were confirmed
as  associated  with  EBV  infectivity  and  most  of  them
characterized  by  the  latency  III  pattern  of  expressed
genes, although Latency I and Latency II forms of EBV
were occasionally also observed [159]. In these PTLDs,
EBV-negative cases  were also reported;  however,  they
are more seen as T cell lymphomas than B cell tumors
and characterized by cellular monomorphic picture, later
presentation  and  more  aggressive  as  compared  to  the
EBV-positive tumors [160, 161].
The variations among the PTLDs in their incidences
and  clinical  manifestations  were  seen  as  dependent  on
the  number  of  the  immunosuppressive  drug  used  and
their doses, the period of the immunosuppressive status
and the type of the tissues transplanted. Common clinical
presentations  are  frequently  observed  as  diversified
extranodal  lesions  such  as  those  seen  in  the
gastrointestinal  tract  or  in  the  organ  transplanted.  The
frequent  occurrence  of  these  PTLDs  in  the  organ
transplanted  was  explained  by  the  fact  that  continuous
and  chronic  antigenic  stimulation  in  the  graft  tissues
stimulates  the  development  and  pathogenesis  of  these
lesions.  In  another  study  involving  SCID  mice,  it  was
reported that T cells were also mandatory for PTLD like
tumors to develop and this suggests a crucial role of T
cells  in  the  growth  of  these  B  cells  lymphoid  tumors
[162].
At  the  cellular  level,  chromosomal  imbalances  and
genomic  alterations  in  EBV  positive  PTLDs  were
detected in some studies and were also proposed to play
an important role in the development and progression of
EBV  induced-lymphoproliferations  and  their  clinical
significance [163, 164]. On the EBV side, LMP1 is the
major  proto-oncogene  that  is  expressed  in  most  EBV-
positive  PTLDs and there  is  an  intimate  association of
EBV  LMP1  deletion  mutants  with  the  PTLDs
morphology,  PTLDs  clonality  and  EBV strain  subtype
[165].
Antiviral chemotherapy, cytokine therapy, cytotoxic
chemotherapy,  anti-  B  cells  antibodies,  cellular
immunotherapy  and  local  treatments  have  all  been
observed  to  successfully  cure  these  conditions  [166].
T-cells Lymphomas
Beside B cell lymphomas, EBV was also confirmed
in several studies to be associated with multiple kinds of
T-cell  lymphoma.  The  EBV  genome  was  detected  in
some T cell lymphomas in the sinuses and nasal cavity in
patients  from many parts  of  the  world  e.g.  Peru  [167],
Japan [168], USA [169], Taiwan [170], some European
countries [171] and recently from China [172]. In other
studies, EBV was detected to account for about 50% of
T-cells  lymphomas  which  indicates  that  the  tumor
establishment  may  precede  EBV  infection  [173].  That
was  confirmed  following  the  advent  of  more  sensitive
molecular biological  techniques which investigated the
role  of  the  EBV  in  the  development  of  these  T  cell
lymphomas. The association of the EBV infectivity with
the  T-cells  lymphomas  was  also  reported  to  be  site-
specific i.e. EBV was detected in 100% and 20% of the
nasal  and  gastrointestinal  lymphomas  respectively  and
rarely in primary cutaneous T-cell lymphomas [174].
Peculiar phenotypic and genotypic manifestations for
the  sinonasal  T-cells  lymphomas  were  observed;  these
include the expression of some cellular markers, absence
of  T  cell  antigens  and  receptor  gene  rearrangements.
However, the latter was detected recently in some cases
of  skin  T  cells  lymphomas  [175].  It  was  also  reported
that  most  of  the  EBV-positive  T  cell  lymphomas  are
extranodal  and  have  a  cytotoxic  phenotypic  features
[176]. This suggests that such kinds of lymphomas may
occur as  a  result  of  EBV infection of  CTLs during the
killing  action  of  EBV-infected  cells.  As  a  matter  of
etiology and clinical outcome, the nasal NK and T cell
lymphomas  are  considered  the  most  closely  associated
with EBV as well as the most aggressive subtype of non-
Hodgkin lymphoma (NHL) ever recorded.
In  a  genetic  study,  the  mRNAs of  EBNA1,  LMP1,
LMP2  or  BamHI  A  transcripts  in  the  EBV-positive
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peripheral  T  cell  lymphomas  were  detected  suggesting
their  expression.  This study also showed and indicated
that  EBV-positive  T  cell  lymphomas  were  clonally
expanded from a single  EBV-infected cell  with  a  gene
expression  pattern  different  from  that  observed  in
Burkitt's lymphomas or PTLDs but seen similar to that
of the NPC [177].
As  mentioned  earlier,  despite  the  fact  that  EBV-
related  post-transplant  lymphomas  (PTLPDs)  are
predominantly B-cell lymphomas, a reasonable number
of them are known to be T cells-associated. These T-cell
PTLPDs were  observed to  be  inconsistently  associated
with  EBV  infectivity  [178].  Based  on  the  site  of  their
development,  multiple  clinical  and  epidemiological
presentations  were  reported  for  EBV-associated  T  cell
lymphomas:
Peripheral  T  cell  lymphomas  (PTCL):  They  are
diversified types of T cells lymphoproliferative diseases
characterized  by  different  pathological  and  clinical
manifestations.  As  compared  to  B  cell  lymphomas,
PTCL are  rare  but  more  difficult  to  manage  and  treat.
PTCL are the most frequently occurring among all types
of T cell lymphomas. In North America, PTCL accounts
for  10–15%  of  all  non-Hodgkin's  lymphomas  in  and
known  to  involve  mature  T  cells  or  NK  cells  [179].
Although  most  of  PTCLs  were  diagnosed  and
recognized  confined  to  the  lymph  nodes,  other  tissues
such as GIT, liver, skin and bone marrow were also seen
involved; such kinds of PTCLs are more aggressive and
cannot  resolve  without  combined  chemotherapy  when
diagnosed. A particular subtype of PTCL known as the
peripheral  T-cell  lymphomas  non-otherwise  specified
(PTCL-  NOS)  is  the  most  commonly  recognized
subtype. PTCL-NOS usually showing extranodal lesions
in  the  liver,  GIT,  spleen  and  bone  marrow  [180].  The
role of EBV in causation of these kinds of lymphomas
has been documented [181, 182].
Anaplastic large cell lymphomas (ALTCL): They are
group  of  lymphomas  characterized  by  proliferation  of
the  large  lymphocytes  and  peculiar  growth
characteristics  and  expression  of  the  cytokine  receptor
CD30. They were firstly described in 1985 as different
types of T cell lymphomas and known to account for 12-
15% of all  T-cell  lymphomas in adults  and around 10-
30% of all lymphomas in children. Depending on the site
where they develop, ALTCL were categorized into three
types: systemic lymphomas, which are usually present in
lymph  nodes,  namely  the  anaplastic  lymphoma  kinase
(ALK) positive and ALK negative lymphoma, based on
the  presence  of  the  ALK protein  on  the  surface  of  the
malignant cell and a third non-systemic type, appearing
only  on  the  skin,  which  is  also  called  a  primary
cutaneous anaplastic large cell lymphoma. As compared
to the skin type, the systemic lymphomas are mostly fast
growing [183]. Although the classification of the WHO
for  the  lymphoid  and  hematopoietic  tumors,  2008
edition,  stated  that  ALCL  is  consistently  negative  for
EBV,  some  studies  have  reported  that  a  correlation
between EBV and ALCL does exist [184, 185]. A case
of ALCL in immunocompetent 35-year-old male using
an  in  situ  hybridization  was  also  proved  positive  for
EBER  in  the  large  neoplastic  cells  [186].
Angioimmunoblastic  Lymphoma  (AIL):  EBV  had
also  been  proposed  as  a  possible  causative  agent
involved  in  the  pathogenesis  of  AILS  which  is  a
progressive and often fatal lymphoproliferative disorder.
It  is  a  fast-growing  T-cell  lymphoma  with  a  primary
symptomatology including swelling of the lymph nodes
as  well  as  systemic  symptoms  like  fever  and  rash.
Generally, this lymphoma is treated as for the other fast
growing  systemic  lymphomas  although  it  may  only
require  mild  therapy  in  certain  conditions  [187].
Previous  findings  also  suggested  that  in  this  type  of
lymphoma  the  T  cells  are  very  vulnerable  to  EBV
persistent  infection  and  that  it  is  more  likely  to  give  a
growth advantage to infected cells. It was concluded that
the pathogenesis of these AIL-TCLs is mediated by three
factors,  EBV  infectivity,  cellular  genetic  defects  and
impairment  in  the  immune  system  [188].
EBV- ASSOCIATED EPITHELIAL TUMORS
In  addition  to  its  role  in  the  hematologic
malignancies,  EBV  has  also  been  known  to  be
implicated  in  both  epithelial  and  mesenchymal
neoplasms.  The  mechanism  whereby  EBV  enters
epithelial  cells,  previously  cited  in  this  review,  was
debated for some time, and some studies have confirmed
a  role  for  CD21  as  receptors  for  the  virus  in  human
epithelial cells [189, 190]. These receptors seen to play a
similar  role  in  the  fresh tissues  of  the  liver,  skin,  GIT,
endothelium, renal tubules, striated muscles and parotid
glands  [191].  It  was  also  reported  that  the  secretory
component-mediated  IgA  transport,  in  which  the
mucosal polymeric immunoglobulin A (pIgA) binds to a
secretory  component,  a  transmembrane  protein
expressed by the epithelium; and is then endocytosed by
the cell, was also proposed as a potential means for EBV
infection of  endothelial  cells  [192].  The mechanism of
cell to cell contact between virus releasing cells and non-
infected epithelial cells for EBV entering and infection
was also reported [193].
Nasopharyngeal  carcinoma  (NPC):  It  is  the  first
epithelial carcinoma known to be associated with EBV
infectivity  [194,  195].  This  was  confirmed  by  the
elevated  antibody  titers  against  EBV in  many  cases  of
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NPCs [196] and later when EBV DNA was identified in
extracts  of  NPC  [197].  The  EBV  genome  was  also
detected  in  NPC tissues  using  Southern  blot  technique
suggesting  that  EBV  infection  precedes  the  clonally
expanded  malignant  cells  of  NPC  [198].  It  was  well
established  that  three  factors  are  involved  in  the  NPC
incidence,  EBV  infectivity,  genetic  predisposition  and
some  environmental  factors  which  may  vary  from one
population group to another [199].
Undifferentiated  type  of  NPC  (UNPC)  was
commonly  observed  in  Arctic,  Middle  East  (mainly
North  Africa),  China  and  South-East  Asia.  It  was  also
observed  that  people  of  Chinese  descent  are  the  most
common population showing higher incidences of NPCs.
Beside  these  genetic  and  racial  predisposition,  an
environmental  factors  such  as  food  components  (e.g.
salted  fish)  are  known  to  be  important  contributing
factors  in  NPC  development  [200].  Other  factors
including  history  of  respiratory  infections,  tobacco
smoking and consumption of preserved foods were also
considered environmental factors for NPC development
[201,  202].  As  for  gender  as  a  co-factor,  it  was
recognized and reported that NPC incidences are 2 to 3
fold  higher  in  males  than  females  in  the  populations
investigated  [203].  Based  on  histological  bases,  WHO
classified  NPC  into  three  types:  type  I  (keratinizing
squamous  cell  carcinoma);  type  II  (differentiated  non-
keratinizing  carcinoma)  and  type  III  (undifferentiated
NPC)  [204].
Looking at the genetic basis of NPC development, it
was  confirmed  in  some  studies  that  individuals  who
inherit  certain  human  leukocyte  antigen  (HLA)  gene
alleles,  that  have  reduced  potential  to  present  EBV
antigen  to  immune  cells,  were  proved  to  have  an
increased risk to develop NPC, whereas individuals with
HLA  alleles  that  present  EBV  efficiently  may  have  a
lower risk for NPC [205, 206]. On the EBV side, LMP1
and LMP2 were proved to have a strong influence on the
cells  genetic  expression  and  proliferation  leading  to
highly  invasive  and  malignant  growth  of  NPC.
Additionally,  the  establishment  of  EBV  latency  and
transformation in epithelial cells is considered as a major
contributing element in the development of NPC [207].
In another former study, using selected human sera and
immunoblotting,  it  was  revealed  that  EBNA2,  EBNA3
and EBNA-LP were not  expressed in NPC tumor cells
[208]. However, the EBNA1 and EBERs proteins were
observed  to  be  expressed  in  all  EBV-positive  NPCs
[208, 209]. Expression of LMP2A gene in NPC tumors
was also detected using PCR while the LMP2A protein
was not detected in NPC tumors [210].
Clinically, patients with NPC may be presented with
one  or  more  of  the  following  symptoms;  nasal
obstruction  involving  nasal  discharge,  congestion  and
bleeding. Hearing changes which are usually attributed
to the blockage of the Eustachian tube may also be seen.
Palsies of the cranial  nerve due to the extension of the
NPC  tumor  into  the  skull  base  causing  headache  and
neck  swelling  were  also  observed  in  some  cases  as
described  by  Sham  et  al.  (1990)  [211].  Some  other
malignancies  with  similar  clinical  features  to  NPC  in
sites  like  tonsils,  lungs,  skin,  thymus,  salivary  glands,
stomach,  breast  and  uterine  cervix  were  also  observed
and referred to as undifferentiated type of NPCs [212 -
216].
Gastric carcinoma (GC): Diffuse gastric or intestinal
adenocarcinomas  were  detected  and  also  proved  to  be
associated  with  EBV  in  about  10%  of  the  total  cases
throughout the world [20, 217, 218]. EBV-negative GCs
were also reported in the majority of cases [219].
EBV-positive GCs were more commonly observed to
occur in males than females [20, 218]. No age preference
for  the  occurrence  of  these  kinds  of  carcinomas  was
observed, however, some studies' findings revealed more
EBV-positive  tumors  in  older  people  compared  to
children or young adults [38, 219, 220]. They were more
likely to occur in the cardia or body of the stomach than
the gastric antrum [6, 218, 221] and most of them were
detected  as  undifferentiated  tumors  [6,  38,  218,  222].
EBV-positive GC is a non endemic disease detected in
all parts of the world. However, high incidence rates of
the disease were recognized in certain regions with the
highest  incidences  recorded  in  Germany and  USA and
the  lowest  in  China  [20,  223  -  226].  In  an
epidemiological  study  in  USA,  EBV-positive  GC  was
more  commonly  observed  among  Hispanics  than  in
Whites  or  African  Americans.  This  indicates  that  the
correlation of GC development with the EBV infectivity
varies  with  the  different  ethnic  groups  of  population
[227].
Advanced  molecular  studies  for  these  type  of
carcinomas showed a restricted genetic expression which
was confined to EBERs, EBNA1 and the BZLF1 with a
reasonable  expression  of  either  LMP1  or  the  other
EBNAs  [21,  228].  Also,  EBV-  encoded  small  RNAs
were seen expressed in every GC cells, this indicates the
importance  of  this  molecule  in  development  and
persistence of the GC [229]. In another proteomic study,
EBV-positive  GC  was  found  to  have  distinct  protein
expression  profile  and  clinicopathological  features  as
compared  to  EBV-negative  carcinoma  [230].
As  for  the  clinical  presentation  of  EBV-associated
GCs, they appear as tumors in the non antrum part of the
stomach accompanied by ulcers in the upper part of the
Clinical & Epidemiological Revisits The Open Virology Journal, 2015, Volume 9   19
stomach when endoscopy was used. It is unlike chronic
gastritis and carcinoma attributed to Helicobacter pylori
(Hp), which locates predominantly in the antrum of the
stomach  [229].  However,  Yani  et  al.  in  1999  [231]
showed that EBV-positive GCs are commonly observed
adjacent to the mucosal atrophic border, where mild to
moderately  chronic  atrophic  gastritis  (CAG)  is
commonly observed. Also EBV and Hp were frequently
detected in the stomach mucosa with moderate CAG, the
area  where  the  inflammatory  cells  are  in  common  and
not the mucosa with obvious CAG, where inflammatory
cell infiltration is minimal.
Oral  hairy  leucoplakia  (OHL):  It  is  also  known  as
HIV-associated hairy  leukoplakia  [232]  and defined as
white  patches  on  either  sides  of  the  tongue  with  hairy
appearance which cannot be scraped off. This carcinoma
was firstly reported and intensively described by in 1984
Greenspan  et  al.  [233].  As  a  confirmation  for  the
association  of  this  malignancy  with  EBV,  an  electron
microscopic  examination  revealed  a  herpes  virus-like
particle.  Later,  the  role  of  EBV  in  this  tumor  was
confirmed  using  the  DNA  hybridization  and
immunohistochemical  techniques  [234].  A  cyclovir
treatment of this  tumor,  an inhibitor of the herpesvirus
DNA polymerase, resulting in the regression of the OHL
and hence EBV was implicated as a causative agent in its
development [234]. This condition was confirmed to be
due to EBV infectivity when the virus reactivated from
latency because of immunosuppression [235]. OHL was
frequently  observed  as  common  oral  lesions  with
HIV/AIDS and  oral  candidiasis  [236].  This  tumor  was
reported  as  the  most  commonly  HIV/AIDS  associated
condition  and  was  known  mainly  to  occur  in  adults
rather  than  children  and  more  in  males  than  females
[237]. Firstly, OHL was believed is the disease of HIV-
infected  and  homosexual  males  but  later  was  found  to
occur in people other than these two groups [237].
To  determine  the  genetic  behavior  of  EBV  during
OHL  oncogenesis,  a  genomic  study  using  Northern
blotting  and  sequencing  to  study  the  EBV  gene
expression  dealing  with  clones  from  a  cDNA  library
constructed using RNA isolated from OHL biopsies was
made. This analysis revealed the expression of BdRF1,
BCRF1,  gp350/220,  BARF0,  and  BKRF4  reading
frames whereas EBNA1, EBNA2 and EBNA -3A RNA
were not seen expressed [238].
No  exact  symptomatology  and  epidemiological
patterns  connected  to  this  tumor  were  reported.
However,  generally  symptoms  and  signs  linked  to
immunosuppression  were  the  majors  symptoms  to  be
detected.  Lesions  were  described  previously  as  white
patches  on  the  lateral  surfaces  of  the  tongue  and  may
involve the dorsum of the tongue but they are rarely seen
on  the  buccal  mucosa,  pharynx,  esophagus  and  soft
palate.  These  lesions  textured  as  vertical  corrugation
(hairy),  or  as  thick  furrow  or  appears  shaggy  [239].
EBV STRATIGIES FOR IMMUNE EVASION
EBV  immune  evasion  is  the  principal  issue  to  be
highlighted here as the well-known lifelong persistence
of  the  virus  in  the  infected  cells  which  has  been
attributed to the virus' strong potential to escape from the
host's  immune  responses.  EBV  was  recognized  as  a
powerful  immunogenic  virus  upon  infection.  This  was
clearly demonstrated by the high levels of  the immune
responses  elicited,  especially  during  the  primary
infection. However, in order for the EBV to survive and
successfully  establish  itself  as  a  latent  virus  in  the
memory  B  cells  of  the  adult,  it  has  a  farrago  of
mechanisms to escape the host immune responses. These
include  shut  down  of  the  most  immune  responsive
proteins  via  the  lytic  proteins  which  interfere  with
antigen  processing  and  with  expression  of  the  MHC
molecules  in  the  infected  cells.  Additionally,  viral
homologues  of  human  cytokines  are  produced  by  the
infected  cells  to  mimic  host  antigens.  These  strategies
and  mechanisms  for  EBV-mediated  immune  evasion
were intensively reviewed by Ressing et al.  [240]. The
limited subset  of  viral  gene products  during latency as
compared  to  the  expression  of  about  80  EBV  gene
products  detected  during  the  replicative  phase  is  also
considered  a  kind  of  immune  evasion  [240].  To
specifically  address  this  issue,  a  protein  encoded  by
EBV, namely BNLF2a, had been identified and normally
expressed  in  the  early  phases  of  the  lytic  replication
cycle of the virus. This protein was known as an immune
evasion protein. It was recognized to inhibit the peptide-
and ATP-binding functions of the transporter associated
with  the  antigen  processing  steps  during  the  immune
response. In addition, this protein expression resulted in
decreased  MHC class  I  expression  and  thus  prevented
the  presentations  of  the  viral  antigens  to  CD8+  CTLs
[241]  and  EBNA1,  a  major  latent  gene  products  is  a
poorly  recognized  protein  by  CD8+  T  lymphocytes
[240]. It was also recently shown that the BCRF1 genes
encoded by the  EBV, which are  homologues  of  IL-10,
are immunoevasins in EBV's lytic cycle [242].
Despite  all  these  strategies  adopted  by  EBV  for
immune  escape,  the  development  of  the  previously
mentioned  tumors  has  been  attributed  to  some
imbalances in the equilibrium between the inherent virus
transforming  properties  and  the  host  immune  system
[243]. Overall, the evasion by EBV of the host's immune
responses  allows  the  virus  to  remain  in  the  body  as  a
latent infection for life whereas reactivation of the latent
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EBV  comes  as  a  consequence  of  immunosuppression
and  the  reactivated  virus  may  transform  the  infected
cells.
CONCLUSION
The  present  review  provides  comprehensive
coverage of some epidemiological and clinical aspects of
EBV-associated  lymphoid  and  epithelial  malignancies
and relates the association of each of these tumors with
EBV  infectivity.  The  genetic  basis  of  tumorigenicity,
including  both  EBV  and  cellular  gene  expression
underlying cancer formation was also reviewed for these
malignancies. All of the tumors mentioned in this review
were found to be EBV-positive; however, some of them
may also have EBV-negative correlation e.g. Hodgkin's
disease and gastric carcinomas.
Different epidemiological patterns were reported for
these tumors depending on the geographical distribution,
ethnic group of people, host age and gender...etc. Some
of these tumors showed racial restrictions (e.g. NPC was
known  to  be  having  special  affinity  to  Asians  as
compared to other ethnic groups) while other co-factors
like  smoke,  salted  food intake  and other  kinds  of  food
were also observed to be linked to some of these tumors
as  predisposing  factors.  Generally,  different  clinical
presentations were reported for different tumors and this
was governed by the tissues and sites affected as well as
the complications that develop.
Generally, the various genetic mechanisms adopted
by  EBV  to  induce  tumorigenesis  of  infected  cells  are
complex,  but  orchestrated  processes.  These  include
expression  of  some  viral  proteins  and  shut  down  of
others.  The expression of  the latent  genes of  the virus,
namely LMP1, LMP2A, LMP2B, EBNA1 and EBNA2,
was  important  with  LMP1  reported  as  the  principal
oncogenic factor of EBV while LMP2 as a mediator of
tumor  cell  survival.  EBNA1  is  the  protein  required  to
bind  the  EBV  genome  to  host  chromosomes  and  thus
allow the transfer of the viral DNA to the progeny cells
during cellular multiplication. EBNA2 is a transactivator
of LMP1. These EBV-associated malignancies develop
despite  strong  immune  responses  to  the  virus  but  the
virus  adopt  several  strategies  for  immune  evasion
including expression of latent genes during the latency
stage. In conclusion, an improved understanding of the
molecular  mechanisms  leading  to  the  development  of
these  malignancies,  which  has  accumulated  in  recent
years,  may  surely  come  up  with  better  prognostic,
treatment  and  management  regimens  for  them  in  the
future.
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